This page ranks companies developing neurodegenerative disease treatments based on pipeline strength, market position, and therapeutic innovation.
| Rank | Company | Pipeline Score | Market Position | Innovation |
|------|---------|---------------|-----------------|------------|
| 1 | Eli Lilly | 95 | Leader | High |
| 2 | Biogen | 90 | Leader | High |
| 3 | Roche | 88 | Strong | High |
| 4 | Eisai | 85 | Strong | Moderate |
| 5 | Janssen | 78 | Growing | Moderate |
| 6 | Prothelia | 72 | Emerging | High |
| 7 | AC Immune | 70 | Emerging | High |
| 8 | Alzheon | 65 | Emerging | Moderate |
| Rank |
Company |
Pipeline Score |
Market Position |
Innovation |
| 1 |
AbbVie |
92 |
Leader |
High |
| 2 |
Novartis |
88 |
Strong |
High |
| 3 |
Roche |
85 |
Strong |
High |
| 4 |
UCB |
80 |
Growing |
Moderate |
| 5 |
Prevail Therapeutics |
75 |
Emerging |
High |
| 6 |
Voyager Therapeutics |
72 |
Emerging |
High |
| 7 |
Inhibikase |
68 |
Emerging |
Moderate |
| 8 |
Sunovion |
65 |
Established |
Moderate |
| Rank |
Company |
Pipeline Score |
Market Position |
Innovation |
| 1 |
Amylyx |
88 |
Leader |
High |
| 2 |
Cytokinetics |
85 |
Strong |
High |
| 3 |
Biogen |
80 |
Strong |
Moderate |
| 4 |
Clene |
75 |
Emerging |
High |
| 5 |
QurAlis |
70 |
Emerging |
Very High |
| 6 |
NeuroSense |
68 |
Emerging |
Moderate |
| 7 |
BrainStorm |
65 |
Emerging |
High |
| Rank |
Company |
Phase 1 |
Phase 2 |
Phase 3 |
| 1 |
Roche |
4 |
3 |
2 |
| 2 |
Biogen |
3 |
3 |
2 |
| 3 |
Eli Lilly |
3 |
2 |
2 |
| 4 |
AbbVie |
2 |
3 |
1 |
| 5 |
Novartis |
2 |
2 |
1 |
| Rank |
Company |
Novel Programs |
Technology Platform |
| 1 |
QurAlis |
3 |
Precision medicine |
| 2 |
Prevail |
2 |
Gene therapy |
| 3 |
Prothelia |
2 |
Tau biology |
| 4 |
AC Immune |
2 |
Vaccine platform |
| 5 |
Clene |
2 |
Nanocatalysis |
| Rank |
Company |
Market Cap |
Pipeline Value |
| 1 |
Eli Lilly |
$700B+ |
High |
| 2 |
Biogen |
$25B |
Moderate |
| 3 |
Roche |
$250B |
High |
| 4 |
AbbVie |
$300B |
Moderate |
| 5 |
Novartis |
$200B |
Moderate |
| Company |
Funding (2024) |
Source |
| QurAlis |
$50M |
Series B |
| Clene |
$42M |
Nasdaq IPO |
| Prevail |
$50M |
Series C |
| Inhibikase |
$25M |
Series B |
| Company |
Phase 1→2 |
Phase 2→3 |
Phase 3→Approval |
| Eli Lilly |
75% |
60% |
80% |
| Biogen |
70% |
55% |
70% |
| Roche |
80% |
65% |
85% |
| AbbVie |
70% |
60% |
75% |
| Novartis |
75% |
55% |
70% |
flowchart TD
subgraph Big_Pharma
A["Biogen"] --> B["Alzheimer's<br/>Aduhelm, Leqembi"]
A --> C["Pipeline<br/>Tau, Synapse"]
D["Eli Lilly"] --> E["Alzheimer's<br/>Donanemab"]
D --> F["Pipeline<br/>Neuroprotection"]
end
subgraph B ["iotech"]
G["Prothelia"] --> H["Protein homeostasis<br/>Prion disease"]
I["Axial Therapeutics"] --> J["Gut-brain axis<br/>PD"]
K["Prevail Therapeutics"] --> L["Gene therapy<br/>GBA 1-PD"]
end
subgraph Platform_Tech
M["CRISPR<br/>Therapeutics"] --> N["Gene editing<br/>Huntington's"]
O["Wave Life Sciences"] --> P["ASO platform<br/>ALS, AD"]
end
subgraph Investment_Flow
B --> Q["FDA Approval"]
C --> R["Clinical trials"]
H --> R
L --> R
N --> R
R --> Q
Q --> S["Commercial launch"]
end
style A fill:#e3f2fd
style D fill:#e3f2fd
style G fill:#e8f5e9
style I fill:#e8f5e9
style K fill:#e8f5e9
style M fill:#fff3e0
style O fill:#fff3e0
style S fill:#c8e6c9
| Category |
Companies |
Focus Area |
Development Stage |
| Big Pharma |
Biogen, Lilly, Roche |
AD/PD |
Late stage |
| Biotech |
Prothelia, Prevail |
Rare disease |
Early-mid |
| Platform |
CRISPR Tx, Wave |
ASO/Gene |
Various |
These ranked items have limited content and would benefit from expansion:
- Company Overview — 6,948 characters